Search

everythinglearnresearchcommunity

for

Search:↓

Platelet-rich plasma is a safe and effective treatment for hair loss, with fewer relapses than steroid treatment.

Platelet-Rich Plasma treatment has limited and temporary effects on severe Alopecia Areata and does not prevent relapses.

Oral tofacitinib helped regrow hair in over half of the patients with severe alopecia, but relapses and side effects were common.

Intravenous methylprednisolone helped over half of alopecia areata patients regrow hair, but many relapsed.

Alopecia areata's causes are unclear, treatments exist but relapses are common.

Alopecia areata was most common in people in their 30s and 40s, with some family history and a higher relapse rate, and larger bald areas responded better to specific immunotherapy.

Alopecia areata involves persistent gene abnormalities and immune activity, even in regrown hair, suggesting a risk of relapse.

Herbal lotions are effective for severe hair loss, with a 64.8% success rate, but relapse is common and long-term management requires allergen control and possible corticosteroid use.

Hair loss from Alopecia Areata is caused by both genes and environment, with several treatments available but challenges in cost and relapse remain.

Younger patients and those with more hair loss are less likely to benefit from oral steroid treatment for hair loss, and low vitamin D may predict relapse.

Intravenous corticosteroid therapy is effective for long-term hair regrowth in alopecia areata, and a scoring system helps predict treatment success and relapse.

No effective treatment for frontal fibrosing alopecia was found, but oral 5-alpha-reductase inhibitors had the best response; for lichen planopilaris, topical corticosteroids were commonly used but had a high relapse rate.

Chinese patients with primary cicatricial alopecia often have folliculitis decalvans, benefit from treatment, but may experience relapse, with dermoscopy being a useful diagnostic tool.

PUVA treatment led to significant hair regrowth in over half of the patients with alopecia areata totalis and universalis.

Diphencyprone (DPC) is an effective and safe long-term treatment for alopecia areata, especially with maintenance therapy.

Bimatoprost was found to be safer and more effective than mometasone furoate for treating scalp hair loss.

Systemic corticosteroids don't prevent severe alopecia areata from spreading or relapsing.

Older age at onset of alopecia areata leads to less severe and shorter episodes, with most patients experiencing significant hair regrowth.

Scalp cooling effectively prevents severe hair loss in breast cancer patients treated with docetaxel and is safe.

People who get alopecia areata after age 50 usually have mild symptoms, high chances of hair regrowth, and often have other health conditions.

Some treatments for severe hair loss work but often have side effects, with baricitinib showing the most promise.

Alopecia areata causes unpredictable hair loss and emotional distress, with no cure and limited treatment options.

Alopecia areata in children is usually mild and effectively treated with strong topical steroids.

Talquetamab may cause hair loss and skin issues.

Alopecia areata can cause unpredictable hair loss, and treatments like corticosteroids and minoxidil may help but have varying side effects.

Zinc supplementation may be an important part of treating severe hair loss.

Abrocitinib, a JAK inhibitor, may help treat atopic dermatitis and alopecia universalis together.

Systemic corticosteroids might help treat hair loss caused by alemtuzumab in MS patients.

Understanding alopecia areata's patterns can improve future research and treatments.

Current corticosteroid pulse therapy is not very effective for severe rapidly progressive alopecia areata.